STAT News, November 16, 2023: Principal Deputy FDA Commissioner Janet Woodcock will retire from the FDA in early 2024 after almost 40 years at the agency, many as a powerful and controversial leader. We explain how her legacy has tarnished the FDA’s reputation.
Read More »Author: Caroline Bradford
NCHR testimony at the FDA Oncologic Drugs Advisory Committee meeting regarding the dangling accelerated approvals of pralatrexate and belinostat for peripheral T-cell lymphoma
November 16, 2023: We believe it necessary for FDA to rescind approval until a trial is completed that confirms meaningful clinical benefits
Read More »Testimony of Diana Zuckerman at FDA Advisory Panel on Blood Irradiators
November 7, 2023: Blood irradiator devices have been used for decades on cancer patients to try to prevent metastasis. NCHR agrees with FDA there is no evidence that they benefit patients and it is clear the radiation can be harmful. At an FDA Advisory Committee meeting in November 2023, we urged FDA to finally require scientific studies if companies want to continue to sell these devices.
Read More »After Drug Trial Fizzles, Sarepta Still Seeks Broad Approval
Bloomberg News, November 1, 2023: Sarepta’s gene therapy Elevidys failed to confirm efficacy for Duchenne Muscular Dystrophy. Will FDA convert accelerated approval to full approval anyway? We explain why that would be ridiculous, but not impossible. But who will pay for an unproven treatment that costs $3.2 million per patient?
Read More »Letter to NJ officials in Montclair and Essex County Regarding Harms from Artificial Turf
October 30, 2023: NCHR president Dr. Diana Zuckerman wrote a letter to NJ officials in Montclair and Essex County explaining why lead, PFAS, and other chemicals in artificial turf and rubber playground surfaces harm children’s health and safety.
Read More »